2. Home
  3. Overview
  4. Diabetes Type 1 and 2

Experimental Stem Cell Secretome Therapy for Diabetes (Type 1 and Type 2) with Mesenchymal Stem Cells at ANOVA IRM in Offenbach, Germany

Diabetes mellitus is a chronic disease in which the body cannot properly regulate blood sugar. Type 1 Diabetes is an autoimmune condition where the immune system destroys the insulin-producing beta cells in the pancreas, leading to little or no insulin production. Type 2 Diabetes is a metabolic disorder in which the body’s cells become resistant to insulin and the pancreas cannot keep up by producing enough insulin. In both types, blood glucose levels become too high, causing symptoms like excessive thirst, frequent urination, fatigue, and unintended weight loss. Over time, high blood sugar can damage the body’s organs, leading to serious complications such as heart disease, nerve damage, kidney failure, and vision loss. Diabetes affects hundreds of millions of people worldwide and currently has no simple cure – management with medications (like insulin) and lifestyle changes is required for life.

ANOVA Institute for Regenerative Medicine (ANOVA IRM) in Germany offers an innovative experimental therapy for Type 1 and Type 2 Diabetes using Mesenchymal Stem Cell (MSCs) secretome. This therapy is being investigated for possible effects on immune regulation and pancreatic function. ANOVA’s Stem Cell Secretome is a cell-free product derived from a patient’s own MSCs, containing the factors (exosomes, growth factors, cytokines) that MSCs release. ANOVA IRM is authorized in Germany to produce and administer this autologous MSC secretome. Laboratory research and early, small clinical studies are examining whether MSC-based approaches influence autoimmune activity and insulin-producing cells. The research questions currently being explored concern, for Type 1, immune activity directed against the pancreas and residual insulin production, and, for Type 2, systemic inflammation, insulin sensitivity, and tissue changes in organs affected by diabetes.

To learn more about our personalized stem cell-based diabetes treatment plans and to discuss if you are a candidate, please contact ANOVA IRM – we are happy to schedule an initial consultation and answer any questions. Below we provide a comprehensive overview of diabetes, current treatments, our MSC therapy approach, and what patients can expect when seeking treatment at ANOVA IRM in Offenbach (near Frankfurt am Main Airport), Germany.

Diabetes Mellitus Overview – Causes, Symptoms, Complications, and Treatments

On this page, we inform you about diabetes and introduce the stem cell-based therapy offered at ANOVA IRM. You will find an overview of the causes, symptoms, and complications of Type 1 and Type 2 diabetes, the conventional therapy options available, and details of our mesenchymal stem cell (MSC) therapy including how it works, the treatment process, and frequently asked questions.

Jump directly to a topic:

MSC Secretome Exosome Therapy | Germany | ANOVA IRM

MSC-Secretome - Exosome - Therapy
ANOVA IRM - Germany

Conventional Diabetes Therapies

Current standard treatments for diabetes focus on managing blood glucose levels and mitigating symptoms. They do not cure the disease or fully stop its progression:

  • Type 1 Diabetes: Since the body produces little to no insulin, patients must take insulin to survive – either through multiple daily injections or an insulin pump. Blood sugar must be monitored frequently. Careful diet and lifestyle management are also crucial. In some cases, physicians may use insulin pump technology or continuous glucose monitors to help maintain control. There are experimental efforts to immunologically modulate Type 1 (for example, medications to suppress the autoimmune attack), but no widely available therapy yet prevents the immune system from attacking the pancreas. Aside from a rare pancreas or islet cell transplant, which involves major surgery and immunosuppressive drugs, there is no way to restore the body’s own insulin production. Thus, Type 1 diabetes is managed life-long by replacing insulin and trying to maintain blood sugar in a safe range. Even with excellent management, patients may experience episodes of high or low blood sugar and remain at risk for long-term complications.
  • Type 2 Diabetes: Treatment typically begins with lifestyle modifications – healthy diet, weight loss, and regular exercise – which can significantly improve blood sugar control. Many patients also take oral medications such as metformin (to reduce glucose production and improve insulin sensitivity) or other drug classes (sulfonylureas, SGLT2 inhibitors, GLP-1 agonists, etc.) to help the body use insulin better or lower blood sugar by other mechanisms. As Type 2 diabetes progresses, the pancreas may produce less insulin over time; some patients eventually require insulin injections as well. These conventional therapies can effectively lower blood sugar and reduce symptoms. However, they generally do not reverse the underlying insulin resistance or loss of beta-cell function – they manage the disease rather than cure it. Many people with Type 2 diabetes face escalating treatment regimens over the years if the disease progresses.
  • Managing Complications: Alongside blood sugar control, conventional therapy involves treating or preventing complications. For example, patients may take medications for blood pressure or cholesterol to reduce cardiovascular risks, undergo regular eye exams for retinopathy, use pain management for neuropathy, etc. Education on foot care and routine medical check-ups are also standard, since complications like foot ulcers can be caught early with proper care.

While these conventional therapies are essential and have drastically improved outcomes for people with diabetes, they have limitations. Insulin and medications must be taken indefinitely and require vigilant daily management. High blood sugar can still occur and cause ongoing damage. Importantly, none of the standard treatments can repair the lost insulin-producing cells or fundamentally alter the course of the disease. This is why researchers and clinics like ANOVA IRM are exploring regenerative approaches such as stem cell therapy – to address the disease at a deeper level.

Stem Cell Therapy for Diabetes – How Can MSCs Help?

Given the challenges of conventional treatments, stem cell-based approaches are being investigated as a research avenue in diabetes. Mesenchymal stem cells (MSCs) have properties that researchers are studying in relation to the mechanisms of both Type 1 and Type 2 diabetes:

  • Immunomodulation: Laboratory research indicates that MSCs interact with immune cells and release signals that can modulate immune responses. Researchers are investigating whether, in Type 1 diabetes, this could influence the autoimmune process directed at pancreatic beta cells. In Type 2 diabetes, research is examining whether MSC-derived signals affect the chronic inflammation associated with insulin resistance. 
  • Regeneration of Pancreatic Function: MSCs secrete growth factors and cytokines (collectively known as the secretome) that are studied in the context of tissue repair. Preclinical findings indicate that these secreted factors can influence beta-cell regeneration and blood-vessel formation in laboratory and animal models. In such models, MSC treatment has been reported to reduce hyperglycemia and to affect pancreatic islet tissue. 
  • Metabolic Control and Complications: Researchers are investigating whether effects on immune regulation and tissue repair seen in the laboratory translate into any effect in patients. Early, small clinical studies have reported changes in blood sugar parameters in some participants – for example lower HbA1c levels (a measure of 3-month blood glucose average) – and reduced insulin requirements in individual cases; temporary insulin independence has been described in a small number of participants. Preclinical research is also examining whether MSC-derived factors influence nerve tissue and blood-vessel formation in animal models of diabetes, and thus whether complications such as neuropathy or impaired wound healing could be affected. 

It’s important to stress that MSC therapy for diabetes is still experimental, but results so far have been encouraging. In clinical research (including multiple trials in humans), MSC treatments have demonstrated the following outcomes:

  • Blood glucose parameters: Some early studies reported a decrease in HbA1c (glycated hemoglobin) from baseline in some participants. 
  • Insulin requirements: Some early studies reported a reduced need for injected insulin in individual participants, and temporary insulin independence was described in isolated Type 1 cases. 
  • Beta-cell biomarkers: Improved beta-cell function: Biomarkers of the pancreas’s insulin production, such as C-peptide levels, have been observed to increase in some patients after MSC therapy, suggesting a possible restoration of beta cell function.
  • Safety and tolerability: No major side effects have been reported in published trials. MSC infusions were generally well-tolerated, with only minor transient reactions noted in a few cases. The use of autologous material is intended to reduce the likelihood of rejection reactions.

Most importantly, MSC therapy is not a cure for diabetes, and no benefit can be promised to any individual patient. Whether MSC-based approaches can influence the course of the disease and to what extent, is the subject of ongoing research. By reducing autoimmunity and stimulating regeneration, MSC treatments could give patients better control of their diabetes and improve their quality of life.

ANOVA IRM, a German stem cell clinic, offers ANOVA’s Stem Cell Secretome – a cell-free MSC preparation – as an experimental option for patients with diabetes. It is based on the secreted factors of MSCs rather than on the transplantation of live cells. ANOVA IRM holds the regulatory authorizations required in Germany to produce and administer this preparation and works under the applicable quality and manufacturing requirements.

If you are interested in our stem cell-based diabetes therapy, check your eligibility and apply for treatment or simply reach out to us for more information. Our medical team will review your case individually and guide you through your options. Please use our contact form or call us for further information and to schedule an appointment.

Comparison: Conventional Therapies vs. MSC-Based Therapy

The table below highlights key differences between traditional diabetes treatments and the experimental MSC-based stem cell therapy offered at ANOVA IRM:

Aspect
Conventional Diabetes Treatment
MSC-Based Stem Cell Therapy
Primary Aim
Control blood glucose and manage symptoms to prevent complications
Modulate the disease process: calm autoimmune attack and repair damaged tissue (restore insulin function)
Approach
Medications (insulin, pills) and lifestyle changes to adjust glucose levels
Regenerative medicine: infusions of patient’s own stem cell secretions to improve the body’s insulin production and regulation
Administration
Daily drug intake (injections, oral meds) and continuous glucose monitoring
A series of medical procedures (fat tissue harvest and IV infusions of stem cell secretome) at a clinic over a period of time
Frequency & Duration
Continuous, lifelong management (medications taken daily/ongoing)
Periodic treatments over a defined course (e.g. several infusions over months to years, with potential repeat courses)
Effect on Disease
Manages the symptoms and slows progression but does not reverse autoimmunity or permanently restore insulin production (no cure)
Aims to modify the underlying disease: aims to preserve or regenerate beta cells and reduce insulin resistance – experimental and not guaranteed to cure
Benefits
Proven to reduce symptoms and risk of complications when adhered to
Small early studies show improved blood sugar control (lower HbA1c) and reduced insulin needs; potential long-term improvement in pancreatic function
Side Effects/Risks
Possible side effects of medications (e.g. insulin can cause low blood sugar, pills can have gastrointestinal side effects); risk of weight gain with some therapies
Thus far, no major adverse effects reported in clinical trials of MSC therapy (minor risks include mild fever or local injection site pain; liposuction carries small procedure risks)
Availability & Regulation
Widely available and well-regulated standard care; typically covered by insurance
Experimental therapy available at specialized clinics (like ANOVA IRM) under regulated clinical protocols; not yet part of standard care (offered under experimental/compassionate use frameworks)
Cost & Insurance
Generally covered by national health systems or insurance; out-of-pocket costs are relatively low (co-pays, etc.)
Not covered by most insurance due to experimental status; typically expensive (out-of-pocket, in the range of tens of thousands of Euros for a full course)
Table: Comparing conventional diabetes management with MSC-based stem cell therapy.

Stem Cell Treatment for Diabetes at ANOVA IRM – Secretome/Exosomes of MSC

Potency Hypothesis of Stem Cell Therapies

Why are stem cells being investigated in complex conditions such as diabetes? The potency hypothesis of MSC therapy is a scientific working hypothesis: it proposes that MSCs may act through several mechanisms at once rather than on a single target. In laboratory research, MSCs respond to signals of injury or inflammation by secreting factors; preclinical work suggests they interact with immune cells and, through mechanisms that are not fully understood, can dampen immune over-reactions in experimental systems, while also releasing growth factors that are studied in the context of tissue regeneration. Applied to diabetes, the hypothesis asks whether MSC-derived factors could act both on immune activity (in Type 1) and on pancreatic or other affected tissue. 

MSEC – Mesenchymal Stem Cell Secretome (Exosomes) – Autologous Therapy

ANOVA IRM’s approach for diabetes uses the secreted factors of MSCs rather than injecting live cells. We use MSEC (Mesenchymal Stem Cell Exosome/Secretome) therapy – a cell-free product derived from your own MSCs. Here’s how the process works in practice:

  1. We obtain a source of MSCs from the patient’s adipose tissue (body fat) via a mini-liposuction, a brief and minimally invasive procedure.
  2. In our GMP-certified laboratory, we isolate and culture these cells to expand their numbers and to produce the secretome (exosomes, growth factors, cytokines).
  3. After production, the cellular material is removed, leaving a purified MSC secretome product, which is quality-tested.
  4. The MSC secretome is delivered back to the patient via injections or infusions (typically intravenous for diabetes).

Worldwide, ANOVA IRM was the first stem cell clinic to obtain legal permission from regulatory authorities to produce and use this kind of autologous exosome-rich secretome therapy. Our MSC secretome is provided under strict oversight for quality and safety, meeting pharmaceutical-grade manufacturing standards.

The main advantage of MSC-derived secretome therapy (MSEC) over traditional cell therapy is its convenience and consistency: the secretome can be frozen and stored without any apparent loss of effectiveness. A single mini-liposuction can yield 10–20 individual doses, allowing for multiple treatment cycles over many months without the need for repeated liposuction procedures.

What exactly are exosomes and secretome? Exosomes are nano-sized vesicles carrying signals. The secretome includes exosomes and all other soluble factors a cell secretes. ANOVA’s preparation is a whole secretome rather than an isolated exosome fraction.

Please note that this treatment is not a cure for diabetes; it is an experimental, potential disease-modifying therapy. Patients must continue standard diabetes care. The therapy requires regular travel to our clinic in Offenbach, Germany, for multiple sessions.

MSEC Therapy Process | ANOVA IRM

Mesenchymal Stem Cell Secretome (MSEC)
Autologous Therapy at ANOVA IRM

Contraindications

Our stem cell treatments are experimental, but we only treat patients for whom we believe the risk/benefit ratio indicates treatment based on the state of the art, i.e., medical, scientific evidence.

Please understand that we therefore do not treat patients for whom the following points apply:

  • Active cancer in the last two years
  • Not yet of legal age
  • Existing pregnancy or lactation period
  • Unable to breathe on own, ventilator
  • Difficulty breathing in supine position
  • Dysphagia (extreme difficulty swallowing)
  • Psychiatric disorder
  • Active infectious disease (Hepatitis A, B, C, HIV, Syphilis, or other)

Therapy Workflow for Diabetes – Treatment Process at ANOVA IRM

The treatment process for undergoing MSC secretome therapy at ANOVA IRM is carefully structured and typically occurs in several phases. The overall workflow is similar for both Type 1 and Type 2 diabetes patients. Here is what you can generally expect:

  1. Initial Evaluation and Consultation: Remote review of medical records, consultation (phone/video) to assess suitability and answer questions.
  2. Pre-Treatment Work-up: Personalized treatment plan, necessary diagnostic tests, cost estimate, regulatory paperwork.
  3. Tissue Harvest (Mini-Liposuction Procedure): Visit Offenbach, Germany (typically 2 days). Minor procedure under local anesthesia/sedation to extract fat tissue.
  4. MSC Processing and Secretome Production: Lab isolates MSCs, cultures them, produces and quality-tests the secretome (~4 weeks, patient returns home).
  5. Treatment Delivery (Secretome Infusions/Injections): Return visits to ANOVA IRM for treatment sessions (e.g., IV infusions). Multiple sessions scheduled over months (e.g., every 4-8 weeks).
  6. Follow-Up and Monitoring: Track progress (HbA1c, insulin needs, C-peptide, symptoms), coordinate with local doctors, monitor for side effects, evaluate need for further treatment.

In summary, the process involves an initial remote evaluation, a short visit for cell harvesting, a wait of a few weeks, then multiple return visits for infusions. The diagram below summarizes the treatment workflow:

Step
Description
Timeline
1. Initial Consultation
Remote review of your medical history, doctor consultation (phone/online) to assess suitability and explain therapy.
Weeks 0–2 (approx.)
2. Treatment Planning
Personalized plan and cost estimate prepared. Any necessary tests done locally.
Weeks 1–3 (concurrent)
3. Fat Harvest Procedure
Travel to ANOVA IRM in Germany for mini-liposuction to collect adipose stem cells (outpatient, 1–2 day visit).
Month 1 (2-day trip)
4. Lab Processing
MSCs from fat are expanded and secretome is produced in lab. Quality checks performed. No patient presence needed during this time.
~4 weeks after harvest
5. Treatment Sessions
Begin regular infusions of the MSC secretome. Each session is a brief outpatient visit (e.g., IV infusion). Multiple doses given over several months.
Months 2–12 (several short trips, e.g. every 4–8 weeks)
6. Follow-Up & Evaluation
Ongoing monitoring of blood sugar control and health. Adjust standard therapy as needed. After completing planned doses, assess results. Consider further therapy if beneficial (may require new cell harvest after ~2 years).
Months 6–24 and beyond
Table: Summary of a typical MSC therapy workflow for diabetes at ANOVA IRM.

 

Every patient’s case is unique, so the above timeline can vary. We strive to tailor the process to your needs and minimize inconvenience. Our team assists with logistics like scheduling, travel advice, and visa documentation if needed.

How Much Does Stem Cell Treatment Cost?

We provide individualized treatments, so the cost varies based on the number of doses, complexity, etc. A personalized cost estimate is provided after evaluation. As a guideline, a full MSC secretome therapy program for diabetes costs in the five-figure range (well above ten thousand Euros). This covers cell harvesting, lab processing, quality controls, administration of multiple doses, and medical supervision. We are transparent about costs upfront.

Does My Health Insurance Cover the Therapy?

Unfortunately, health insurance companies do not currently cover experimental treatments like MSC secretome therapy. It is not yet standard care. Patients must typically bear the costs out-of-pocket, including travel. We provide detailed invoices for potential submission to tax authorities or healthcare savings accounts where applicable. ANOVA IRM is a private clinic requiring direct payment. We can provide information if you seek crowdfunding or other funding options.

(For any cost or payment-related inquiries, feel free to contact our patient care coordinators via the contact form.)

Treating Diabetes at ANOVA IRM – Our Approach

At ANOVA IRM, our mission is to provide personalized, high-quality regenerative treatments responsibly. Our approach includes:

  • Combination of Established and Novel Therapies: We advise continuing conventional therapy alongside regenerative treatment, working with your primary doctors.
  • Thorough Diagnostics and Monitoring: Comprehensive work-ups establish baselines and track progress objectively, allowing for personalized adjustments.
  • Science-Based Protocols: Our protocols draw on the available scientific literature, which for this indication is early and limited. We set realistic expectations and explain the experimental character of the therapy.
  • Ethics and Patient Safety: We adhere to strict ethical standards, conduct risk-benefit analyses, obtain informed consent, and prioritize well-being. Our clinic operates under stringent German healthcare regulations.

Make an appointment today to learn more about your treatment options at ANOVA IRM. Our team is dedicated to offering cutting-edge therapy with compassion and professionalism.

(Use our contact form or phone number to get in touch – we typically respond within 1–2 business days.)

Stem Cell-Based Treatment for Diabetes: Your Personalized, High-Quality Therapy

ANOVA IRM applies current scientific knowledge in its stem cell secretome program:

  • Quality and Regulatory Compliance: Legally authorized, regularly audited processes with quality control in line with the applicable pharmaceutical manufacturing requirements.
  • Laboratory: Standardized manufacturing procedures, trained staff, and established characterization methods.
  • Advanced Diagnostics Integration: Modern diagnostics (blood tests, imaging if needed) used throughout to monitor progress and guide therapy.
  • Personalized Treatment and Follow-up: Therapy plan tailored to individual needs and response. Continuous assessment and long-term follow-up.

We aim to provide careful, well-documented care within our stem cell secretome program for diabetes. We understand the significance of seeking experimental treatment abroad and support you throughout the process.

Important: While optimistic, we remain realistic. This treatment is innovative, and results vary. We cannot guarantee improvement for every patient but promise to apply our expertise fully. If stem cell therapy is unsuitable, we will provide honest guidance.

To find out more about your specific case, please contact us for a detailed consultation. ANOVA IRM is a private clinic specializing in regenerative medicine since 2016.

FAQ: Stem Cell-Based Therapies for Diabetes

Below we address some frequently asked questions patients have about diabetes and the MSC therapy offered at ANOVA IRM.

What is Type 1 Diabetes?

Type 1 Diabetes (T1D) is an autoimmune disease where the immune system destroys insulin-producing beta cells in the pancreas, leading to little or no insulin production. Glucose builds up in the blood (hyperglycemia). Symptoms often appear suddenly and include extreme thirst, frequent urination, weight loss, fatigue, and blurred vision. Untreated, it can lead to diabetic ketoacidosis (DKA). T1D often starts in childhood/young adulthood but can occur at any age. It requires lifelong insulin therapy and monitoring. There is no cure or prevention method currently.

What is Type 2 Diabetes?

Type 2 Diabetes (T2D) is the most common form (~90% of cases), characterized by insulin resistance (cells don't respond well to insulin) and eventually reduced insulin production. Risk factors include overweight/obesity, inactivity, family history, and ethnicity. It usually develops gradually in adults but is increasing in younger people. Symptoms are similar to T1D but milder initially; some have no symptoms for years. T2D is progressive and often requires lifestyle changes, oral medications, and sometimes insulin. It can often be prevented or delayed with healthy habits.

What are the Symptoms of Diabetes?

Common signs for both types include:

  • Excessive thirst (polydipsia) and dry mouth.
  • Frequent urination (polyuria).
  • Extreme hunger (polyphagia).
  • Fatigue and weakness.
  • Blurred vision.
  • Slow-healing wounds or frequent infections.
  • Unexplained weight loss (more common in T1D).
  • Numbness or tingling in hands or feet (neuropathy).

T1D symptoms usually appear quickly; T2D symptoms develop slowly. Seek medical evaluation if you experience these signs.

What are the Complications of Diabetes?

Chronic high blood sugar damages blood vessels and nerves, leading to:

  • Acute Complications: Diabetic Ketoacidosis (DKA, mainly T1D), Hyperosmolar Hyperglycemic State (HHS, mainly T2D), severe hypoglycemia (low blood sugar from treatment). These are emergencies.
  • Long-Term Complications: Cardiovascular disease (heart attack, stroke), neuropathy (nerve damage, especially feet), nephropathy (kidney damage/failure), retinopathy (eye damage/blindness), foot problems (ulcers, infections, amputation risk), skin conditions, digestive issues (gastroparesis), sexual dysfunction, hearing loss, dental problems.

Good blood sugar control significantly reduces complication risk. MSC therapy aims to improve control and potentially reduce long-term damage.

How does the MSC Secretome Therapy actually work for Diabetes?

The MSC secretome contains signalling factors. Scientific research is investigating whether, in T1D, these factors influence immune activity directed at the pancreas and beta-cell function, and whether, in T2D, they affect inflammation, insulin sensitivity, and blood-vessel formation. Because the preparation is given as a series of infusions, any changes would be assessed over a period of weeks to months.

Is MSC Stem Cell Therapy a Cure for Diabetes?

No, MSC therapy is not a cure. It's an experimental therapy that aims to improve the condition and potentially induce partial remission, but not eliminate diabetes permanently. In early studies, temporary insulin independence was described in individual T1D participants, who generally resumed insulin later. Any effect observed may be transient. The therapy is not a replacement for standard care and no individual response can be predicted.

Who is Eligible for Stem Cell Therapy for Diabetes at ANOVA IRM?

Eligibility is case-by-case, generally:

  • Adults (18+) with confirmed T1D or T2D.
  • Medically stable for travel and minor procedure.
  • Both recent-onset and long-term T1D considered.
  • T2D patients with difficulty controlling diabetes or complications may be candidates.
  • No contraindications (active cancer, pregnancy, severe unstable illness, active infection, etc.).
  • Able to consent and participate, with realistic expectations.

Contact us with medical information for an assessment.

What does the treatment involve – do I have to get surgery?

It involves a mini-liposuction (minor procedure under local anesthesia/sedation to get fat), blood draws, lab processing (patient not present), and then intravenous infusions of the secretome (outpatient sessions). No major surgery is involved. The liposuction has quick recovery. Infusions are like getting an IV medicine drip.

How often do I need to come to Germany for this treatment?

You'll make an initial 2-day trip for the liposuction. After ~4 weeks, you'll return for infusion sessions. A typical schedule might involve 4-6 visits in the first year (e.g., every 4-8 weeks). Each visit might be 1-2 days. We can adjust scheduling for international travelers (e.g., clustering infusions). The stored secretome lasts up to 2 years, allowing flexibility.

How soon might I see results, and how will I know if it’s working?

No response can be promised, and it is possible that nothing changes. Because this is an experimental therapy, we do not work with an expected timeline of improvement. What we do define in advance is what should be measured: glucose readings and variability, insulin dose, laboratory values such as HbA1c and C-peptide, and the symptoms you report. These parameters should be assessed across the treatment course.

Is the MSC therapy safe? What are the risks and side effects?

MSC therapy has a strong safety profile. Using autologous material minimizes rejection/allergic reactions. No serious adverse events directly linked to MSC/secretome therapy reported in major trials. Known and potential risks include:

  • Infusion: Transient side effects such as mild fever, chills, headache, or nausea are possible.
  • Liposuction: Risks such as bruising, soreness, numbness, and, more rarely, infection or bleeding.
  • Hypoglycemia: If your diabetes medication is adjusted during the treatment period, low blood sugar can occur. Any change to insulin dosing must be made together with your treating physician and requires monitoring.
  • Long-term: No known long-term risks; secretome is cell-free, avoiding risks of unwanted cell growth.

Alongside the medical risks, you should also weigh the financial cost, the travel burden, and the fact that a benefit is uncertain and cannot be promised.

What characterises ANOVA IRM’s approach?

Key features of our programme:

  • Cell-free Secretome Approach: We work with the secretome of MSCs rather than with living cells.
  • Autologous Therapy: The patient's own cells are used as the starting material, manufactured under German regulatory oversight.
  • Holistic Care & Follow-up: Integrated treatment, diagnostics, collaboration with other doctors, long-term monitoring.
  • Experienced Team: Physicians and scientists with many years of experience in regenerative medicine.
  • Legal & Ethical Compliance: Operating transparently within legal frameworks.
  • Regenerative Options: Depending on the individual case, different regenerative preparations (e.g. BMC, Secretome) may be discussed.

How can I get started or learn more about receiving treatment?

Contact us via our online form, email, or phone. We'll request medical records (doctor's summary, labs like HbA1c/C-peptide, medication list, complication reports). Our team reviews your case, followed by a remote consultation with a doctor to discuss suitability, the process, and answer questions. If eligible and you decide to proceed, we provide a treatment proposal, consent forms, and assist with scheduling and travel logistics. A dedicated patient liaison supports you throughout.

We hope this information page has been helpful. Diabetes is challenging, and research into approaches such as the MSC secretome is ongoing. At ANOVA IRM, we combine scientific care with attentive support. Please contact us with further questions.

Ready to take the next step? – Reach out to us today to schedule your personalized consultation.

Sources and Literature

(A selection of scientific references and sources that inform our therapy and the content above):

  1. Yang L et al., 2021 – Stem Cell Research & Therapy: Meta-analysis reporting glycaemic changes after MSC transplantation, mainly in T1D; insulin independence was described in individual T2D participants. (Links: PMC)
  2. Khatri R et al., 2020 – PubMed: Preclinical study suggesting MSCs promote pancreatic β-cell regeneration via FoxO1 pathway downregulation. (Links: PMC)
  3. Kumar D et al., 2025 – World Journal of Stem Cells: Letter discussing the first reported case of insulin independence following transplantation of autologous induced pluripotent stem cell-derived islet cells in a patient with T1D. (Link: PMC)
  4. Chen JT et al., 2025 – Nature Medicine: Review of advances, early clinical trials, and remaining regulatory and immunological challenges associated with stem cell-derived pancreatic islet therapies for diabetes. (Link: Nature Medicine)
  5. Päth G et al., 2019 – Metabolism: Review examining the potential mechanisms and therapeutic applications of MSCs in T1D and T2D, including immunomodulation, β-cell protection, and regeneration. (Link: PubMed)
  6. El-Badawy A and El-Badri N, 2016 – PLOS ONE: Meta-analysis of 22 clinical trials involving 524 participants, evaluating the safety and efficacy of different stem cell therapies in T1D and T2D. (Links: PLOS ONE | PubMed)
  7. de Klerk E and Hebrok M, 2021 – Frontiers in Endocrinology: Review of MSC- and pluripotent stem cell-based clinical trials aimed at protecting, restoring, or replacing pancreatic β cells in diabetes. (Links: PMC | Frontiers)
  8. Sneddon JB et al., 2018 – Cell Stem Cell: Review of progress in generating functional stem cell-derived insulin-producing islet cells and the immune-modulation and encapsulation strategies needed for their transplantation. (Links: PMC | Cell Stem Cell)
  9. American Diabetes Association (ADA): General diabetes information. (Links: Understanding Type 1 Diabetes | ADA)
  10. Centers for Disease Control and Prevention (CDC): General diabetes information. (Links: Type 2 Diabetes | Diabetes | CDC)
  11. Cleveland Clinic: General diabetes information. (Link: Diabetes: What It Is, Causes, Symptoms, Treatment & Types)

(For a full list of references or further reading, please contact ANOVA IRM or see our “Literature” section on the website.)

  1. Georg Hansmann, Philippe Chouvarine, Franziska Diekmann, Martin Giera, Markus Ralser, Michael Mülleder, Constantin von Kaisenberg, Harald Bertram, Ekaterina Legchenko & Ralf Hass "Human umbilical cord mesenchymal stem cell-derived treatment of severe pulmonary arterial hypertension". Nature Cardiovascular Research volume 1, pages568–576 (2022).
  2. Murphy JM, Fink DJ, Hunziker EB, et al. Stem cell therapy in a caprine model of osteoarthritis . Arthritis Rheum. 2003;48:3464–74.
  3. Lee KB, Hui JH, Song IC, Ardany L, et al. Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model. Stem Cell. 2007;25:2964–71.
  4. Saw KY, Hussin P, Loke SC, et al. Articular cartilage regeneration with autologous marrow aspirate and hyaluronic acid: an experimental study in a goat model. Arthroscopy . 2009;25(12):1391–400.
  5. Black L, Gaynor J, Adams C, et al. Effect of intra-articular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 2008;9:192-200.
  6. Centeno C, Busse D, Kisiday J, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008;11(3):343–53.
  7. Centeno C, Kisiday J, Freeman M, et al. Partial regeneration of the human hip via autologous bone marrow nucleated cell transfer: a case study. Pain Physician. 2006;9:253–6.
  8. Centeno C, Schultz J, Cheever M. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell. 2011;5(1):81–93.
  9. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose derived stem cells: a case series. J Med Case Rep. 2001;5:296.
  10. Kuroda R, Ishida K, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage. 2007;15:226–31.
  11. Emadedin M, Aghdami N, Taghiyar L, et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran Med. 2012;15(7):422–8.
  12. Saw KY et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy. 2013;29(4):684–94.
  13. Vangsness CT, Farr J, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy. J Bone Joint Surg. 2014;96(2):90–8.
  14. Freitag, Julien, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy–a review. BMC musculoskeletal disorders 17.1 (2016): 230.
  15. Maumus, Marie, Christian Jorgensen, and Danièle Noël. " Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes. " Biochimie 95.12 (2013): 2229-2234.
  16. Dostert, Gabriel, et al. " How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication?. " Frontiers in Cell and Developmental Biology 5 (2017).
  17. Chaparro, Orlando, and Itali Linero. " Regenerative Medicine: A New Paradigm in Bone Regeneration. " (2016).
  18. Toh, Wei Seong, et al. " MSC exosome as a cell-free MSC therapy for cartilage regeneration: Implications for osteoarthritis treatment. " Seminars in Cell & Developmental Biology. Academic Press, 2016.
  19. Chaparro, Orlando, and Itali Linero. " Regenerative Medicine: A New Paradigm in Bone Regeneration. " (2016).
  20. S. Koelling, J. Kruegel, M. Irmer, J.R. Path, B. Sadowski, X. Miro, et al., Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis , Cell Stem Cell 4 (2009) 324–335.
  21. B.A. Jones, M. Pei, Synovium-Derived stem cells: a tissue-Specific stem cell for cartilage engineering and regeneration , Tissue Eng. B: Rev. 18 (2012) 301–311.
  22. W. Ando, J.J. Kutcher, R. Krawetz, A. Sen, N. Nakamura, C.B. Frank, et al., Clonal analysis of synovial fluid stem cells to characterize and identify stable mesenchymal stromal cell/mesenchymal progenitor cell phenotypes in a porcine model: a cell source with enhanced commitment to the chondrogenic lineage, Cytotherapy 16 (2014) 776–788.
  23. K.B.L. Lee, J.H.P. Hui, I.C. Song, L. Ardany, E.H. Lee, Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model, Stem Cells 25 (2007) 2964–2971.
  24. W.-L. Fu, C.-Y. Zhou, J.-K. Yu, A new source of mesenchymal stem cells for articular cartilage repair: mSCs derived from mobilized peripheral blood share similar biological characteristics in vitro and chondrogenesis in vivo as MSCs from bone marrow in a rabbit model , Am. J. Sports Med. 42 (2014) 592–601.
  25. X. Xie, Y. Wang, C. Zhao, S. Guo, S. Liu, W. Jia, et al., Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration , Biomaterials 33 (2012) 7008–7018.
  26. E.-R. Chiang, H.-L. Ma, J.-P. Wang, C.-L. Liu, T.-H. Chen, S.-C. Hung, Allogeneic mesenchymal stem cells in combination with hyaluronic acid for the treatment of osteoarthritis in rabbits , PLoS One 11 (2016) e0149835.
  27. H. Nejadnik, J.H. Hui, E.P. Feng Choong, B.-C. Tai, E.H. Lee, Autologous bone marrow–derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study , Am. J. Sports Med. 38 (2010) 1110–1116.
  28. I. Sekiya, T. Muneta, M. Horie, H. Koga, Arthroscopic transplantation of synovial stem cells improves clinical outcomes in knees with cartilage defects , Clin. Orthop. Rel. Res. 473 (2015) 2316–2326.
  29. Y.S. Kim, Y.J. Choi, Y.G. Koh, Mesenchymal stem cell implantation in knee osteoarthritis: an assessment of the factors influencing clinical outcomes , Am. J. Sports Med. 43 (2015) 2293–2301.
  30. W.-L. Fu, Y.-F. Ao, X.-Y. Ke, Z.-Z. Zheng, X. Gong, D. Jiang, et al., Repair of large full-thickness cartilage defect by activating endogenous peripheral blood stem cells and autologous periosteum flap transplantation combined with patellofemoral realignment , Knee 21 (2014) 609–612.
  31. Y.-G. Koh, O.-R. Kwon, Y.-S. Kim, Y.-J. Choi, D.-H. Tak, Adipose-derived mesenchymal stem cells with microfracture versus microfracture alone: 2-year follow-up of a prospective randomized trial , Arthrosc. J. Arthrosc. Relat. Surg. 32 (2016) 97–109.
  32. T.S. de Windt, L.A. Vonk, I.C.M. Slaper-Cortenbach, M.P.H. van den Broek, R. Nizak, M.H.P. van Rijen, et al., Allogeneic mesenchymal stem cells stimulate cartilage regeneration and are safe for single-Stage cartilage repair in humans upon mixture with recycled autologous chondrons , Stem Cells (2016) (n/a-n/a).
  33. L. da Silva Meirelles, A.M. Fontes, D.T. Covas, A.I. Caplan, Mechanisms involved in the therapeutic properties of mesenchymal stem cells , Cytokine Growth Factor Rev. 20 (2009) 419–427.
  34. W.S. Toh, C.B. Foldager, M. Pei, J.H.P. Hui, Advances in mesenchymal stem cell-based strategies for cartilage repair and regeneration , Stem Cell Rev. Rep. 10 (2014) 686–696.
  35. R.C. Lai, F. Arslan, M.M. Lee, N.S.K. Sze, A. Choo, T.S. Chen, et al., Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury , Stem Cell Res. 4 (2010) 214–222.
  36. S. Zhang, W.C. Chu, R.C. Lai, S.K. Lim, J.H.P. Hui, W.S. Toh, Exosomes derived from human embryonic mesenchymal stem cells promote osteochondral regeneration, Osteoarthr . Cartil. 24 (2016) 2135–2140.
  37. S. Zhang, W. Chu, R. Lai, J. Hui, E. Lee, S. Lim, et al., 21 – human mesenchymal stem cell-derived exosomes promote orderly cartilage regeneration in an immunocompetent rat osteochondral defect model , Cytotherapy 18 (2016) S13.
  38. C.T. Lim, X. Ren, M.H. Afizah, S. Tarigan-Panjaitan, Z. Yang, Y. Wu, et al., Repair of osteochondral defects with rehydrated freeze-dried oligo[poly(ethylene glycol) fumarate] hydrogels seeded with bone marrow mesenchymal stem cells in a porcine model
  39. A. Gobbi, G. Karnatzikos, S.R. Sankineani, One-step surgery with multipotent stem cells for the treatment of large full-thickness chondral defects of the knee , Am. J. Sports Med. 42 (2014) 648–657.
  40. A. Gobbi, C. Scotti, G. Karnatzikos, A. Mudhigere, M. Castro, G.M. Peretti, One-step surgery with multipotent stem cells and Hyaluronan-based scaffold for the treatment of full-thickness chondral defects of the knee in patients older than 45 years , Knee Surg. Sports Traumatol. Arthrosc. (2016) 1–8.
  41. A. Gobbi, G. Karnatzikos, C. Scotti, V. Mahajan, L. Mazzucco, B. Grigolo, One-step cartilage repair with bone marrow aspirate concentrated cells and collagen matrix in full-thickness knee cartilage lesions: results at 2-Year follow-up , Cartilage 2 (2011) 286–299.
  42. K.L. Wong, K.B.L. Lee, B.C. Tai, P. Law, E.H. Lee, J.H.P. Hui, Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up , Arthrosc. J. Arthrosc. Relat. Surg. 29 (2013) 2020–2028.
  43. J.M. Hare, J.E. Fishman, G. Gerstenblith, et al., Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the poseidon randomized trial, JAMA 308 (2012) 2369–2379.
  44. L. Wu, J.C.H. Leijten, N. Georgi, J.N. Post, C.A. van Blitterswijk, M. Karperien, Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation , Tissue Eng. A 17 (2011) 1425–1436.
  45. L. Wu, H.-J. Prins, M.N. Helder, C.A. van Blitterswijk, M. Karperien, Trophic effects of mesenchymal stem cells in chondrocyte Co-Cultures are independent of culture conditions and cell sources , Tissue Eng. A 18 (2012) 1542–1551.
  46. S.K. Sze, D.P.V. de Kleijn, R.C. Lai, E. Khia Way Tan, H. Zhao, K.S. Yeo, et al., Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells , Mol. Cell. Proteomics 6 (2007) 1680–1689.
  47. M.B. Murphy, K. Moncivais, A.I. Caplan, Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine , Exp. Mol. Med. 45 (2013) e54.
  48. M.J. Lee, J. Kim, M.Y. Kim, Y.-S. Bae, S.H. Ryu, T.G. Lee, et al., Proteomic analysis of tumor necrosis factor--induced secretome of human adipose tissue-derived mesenchymal stem cells , J. Proteome Res. 9 (2010) 1754–1762.
  49. S. Bruno, C. Grange, M.C. Deregibus, R.A. Calogero, S. Saviozzi, F. Collino, et al., Mesenchymal stem cell-derived microvesicles protect against acute tubular injury, J. Am. Soc. Nephrol. 20 (2009) 1053–1067.
  50. M. Yá˜nez-Mó, P.R.-M. Siljander, Z. Andreu, A.B. Zavec, F.E. Borràs, E.I. Buzas, et al. Biological properties of extracellular vesicles and their physiological functions (2015).
  51. C. Lawson, J.M. Vicencio, D.M. Yellon, S.M. Davidson, Microvesicles and exosomes: new players in metabolic and cardiovascular disease , J. Endocrinol. 228 (2016) R57–R71.
  52. A.G. Thompson, E. Gray, S.M. Heman-Ackah, I. Mager, K. Talbot, S.E. Andaloussi, et al., Extracellular vesicles in neurodegenerative diseas—pathogenesis to biomarkers, Nat. Rev. Neurol. 12 (2016) 346–357.
  53. I.E.M. Bank, L. Timmers, C.M. Gijsberts, Y.-N. Zhang, A. Mosterd, J.-W. Wang, et al., The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease , Expert Rev. Mol. Diagn. 15 (2015) 1577–1588.
  54. T. Kato, S. Miyaki, H. Ishitobi, Y. Nakamura, T. Nakasa, M.K. Lotz, et al., Exosomes from IL-1 stimulated synovial fibroblasts induce osteoarthritic changes in articular chondrocytes , Arthritis. Res. Ther. 16 (2014) 1–11.
  55. R.W.Y. Yeo, S.K. Lim, Exosomes and their therapeutic applications, in: C. Gunther, A. Hauser, R. Huss (Eds.), Advances in Pharmaceutical Cell TherapyPrinciples of Cell-Based Biopharmaceuticals, World Scientific, Singapore, 2015, pp. 477–491.
  56. X. Qi, J. Zhang, H. Yuan, Z. Xu, Q. Li, X. Niu, et al., Exosomes secreted by human-Induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats , Int. J. Biol. Sci. 12 (2016) 836–849.
  57. R.C. Lai, F. Arslan, S.S. Tan, B. Tan, A. Choo, M.M. Lee, et al., Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles , J. Mol. Cell. Cardiol. 48 (2010) 1215–1224.
  58. Y. Zhou, H. Xu, W. Xu, B. Wang, H. Wu, Y. Tao, et al., Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro , Stem Cell Res. Ther. 4 (2013) 1–13.
  59. Y. Qin, L. Wang, Z. Gao, G. Chen, C. Zhang, Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo , Sci. Rep. 6 (2016) 21961.
  60. M. Nakano, K. Nagaishi, N. Konari, Y. Saito, T. Chikenji, Y. Mizue, et al., Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into damaged neurons and astrocytes , Sci. Rep. 6 (2016) 24805.
  61. K. Nagaishi, Y. Mizue, T. Chikenji, M. Otani, M. Nakano, N. Konari, et al., Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes , Sci. Rep. 6 (2016) 34842.
  62. S.R. Baglio, K. Rooijers, D. Koppers-Lalic, F.J. Verweij, M. Pérez Lanzón, N. Zini, et al., Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species , Stem Cell Res. Ther. 6 (2015) 1–20.
  63. T. Chen, R. Yeo, F. Arslan, Y. Yin, S. Tan, Efficiency of exosome production correlates inversely with the developmental maturity of MSC donor, J. Stem Cell Res. Ther. 3 (2013) 2.
  64. R.C. Lai, S.S. Tan, B.J. Teh, S.K. Sze, F. Arslan, D.P. de Kleijn, et al., Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome , Int. J. Proteomics 2012 (2012) 971907.
  65. T.S. Chen, R.C. Lai, M.M. Lee, A.B.H. Choo, C.N. Lee, S.K. Lim, Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs , Nucleic Acids Res. 38 (2010) 215–224.
  66. R.W. Yeo, R.C. Lai, K.H. Tan, S.K. Lim, Exosome: a novel and safer therapeutic refinement of mesenchymal stem cell, J. Circ. Biomark. 1 (2013) 7.
  67. R.C. Lai, R.W. Yeo, S.K. Lim, Mesenchymal stem cell exosomes, Semin. Cell Dev. Biol. 40 (2015) 82–88.
  68. B. Zhang, R.W. Yeo, K.H. Tan, S.K. Lim, Focus on extracellular vesicles: therapeutic potential of stem cell-derived extracellular vesicles , Int. J. Mol. Sci. 17 (2016) 174.
  69. Hu G-w, Q. Li, X. Niu, B. Hu, J. Liu, Zhou S-m, et al., Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice , Stem Cell Res. Ther. 6 (2015) 1–15.
  70. J. Zhang, J. Guan, X. Niu, G. Hu, S. Guo, Q. Li, et al., Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis , J. Transl. Med. 13 (2015) 1–14.
  71. B. Zhang, M. Wang, A. Gong, X. Zhang, X. Wu, Y. Zhu, et al., HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing, Stem Cells 33 (2015) 2158–2168.
  72. B. Zhang, Y. Yin, R.C. Lai, S.S. Tan, A.B.H. Choo, S.K. Lim, Mesenchymal stem cells secrete immunologically active exosomes , Stem Cells Dev. 23 (2013) 1233–1244.
  73. C.Y. Tan, R.C. Lai, W. Wong, Y.Y. Dan, S.-K. Lim, H.K. Ho, Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models , Stem Cell Res. Ther. 5 (2014) 1–14.
  74. C. Lee, S.A. Mitsialis, M. Aslam, S.H. Vitali, E. Vergadi, G. Konstantinou, et al., Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension , Circulation 126 (2012) 2601–2611.
  75. B. Yu, H. Shao, C. Su, Y. Jiang, X. Chen, L. Bai, et al., Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1 , Sci. Rep. 6 (2016) 34562.
  76. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof of concept clinical trial. Stem Cells. 2014;32(5):1254–66.
  77. Vega, Aurelio, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99(8):1681–90.
  78. Davatchi F, Sadeghi-Abdollahi B, Mohyeddin M, et al. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011;14(2):211–5
  79. Hernigou P, Flouzat Lachaniette CH, Delambre J, et al. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case- controlled study. Int Orthop. 2014;38(9):1811–1818
  80. Galli D, Vitale M, Vaccarezza M. Bone marrow-derived mesenchymal cell differentiation toward myogenic lineages: facts and perspectives. Biomed Res Int. 2014;2014:6.
  81. Beitzel K, Solovyova O, Cote MP, et al. The future role of mesenchymal Stem cells in The management of shoulder disorders . Arthroscopy. 2013;29(10):1702–1711.
  82. Isaac C, Gharaibeh B, Witt M, Wright VJ, Huard J. Biologic approaches to enhance rotator cuff healing after injury. J Shoulder Elbow Surg. 2012;21(2):181–190.
  83. Malda, Jos, et al. " Extracellular vesicles [mdash] new tool for joint repair and regeneration. " Nature Reviews Rheumatology (2016).

  1. Xu, Ming, et al. " Transplanted senescent cells induce an osteoarthritis-like condition in mice. " The Journals of Gerontology Series A: Biological Sciences and Medical Sciences (2016): glw154.
  2. McCulloch, Kendal, Gary J. Litherland, and Taranjit Singh Rai. " Cellular senescence in osteoarthritis pathology ." Aging Cell (2017).

Contraindications

Our stem cell treatments are experimental, but we only treat patients for whom we believe the risk/benefit ratio indicates treatment based on the state of the art, i.e., medical, scientific evidence.

Please understand that we therefore do not treat patients for whom the following points apply:

  • Active cancer in the last two years
  • Not yet of legal age
  • Existing pregnancy or lactation period
  • Unable to breathe on own, ventilator
  • Difficulty breathing in supine position
  • Dysphagia (extreme difficulty swallowing)
  • Psychiatric disorder
  • Active infectious disease (Hepatitis A, B, C, HIV, Syphilis, or other)